Cardiff Oncology
$1.58
63
-$0.03-1.86% Today
Statistics
Day High
1.6
Day Low
1.55
52W High
4.56
52W Low
1.48
Volume
527,002
Avg. Volume
1,092,178
Mkt Cap
106.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30AprExpected
Expected EPS
-0.134625
Actual EPS
N/A
Financials
-6,655.2%Profit Margin
Unprofitable1.37MRevenue
-90.91MNet Income
Analyst Ratings
$10.00Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CRDF. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap237.61B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Merck
MRK
Mkt Cap214.76B
AMGEN
AMGN
Mkt Cap160.66B
Gilead Sciences
GILD
Mkt Cap148.78B
Pfizer
PFE
Mkt Cap140.15B
Abbvie
ABBV
Mkt Cap385.18B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
About
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Mark Erlander Ph.D.
Employees
32
Country
US
ISIN
US14147L1089
Listings
0 Comments
Share your thoughts
FAQ
What is Cardiff Oncology stock price today?▼
The current price of CRDF is $1.58 USD — it has decreased by -1.86% in the past 24 hours. Watch Cardiff Oncology stock price performance more closely on the chart.
What is Cardiff Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cardiff Oncology stocks are traded under the ticker CRDF.
Is Cardiff Oncology stock price growing?▼
CRDF stock has fallen by -5.39% compared to the previous week, the month change is a -18.56% fall, over the last year Cardiff Oncology has showed a -47.51% decrease.
What is Cardiff Oncology market cap?▼
Today Cardiff Oncology has the market capitalization of 106.43M
When is the next Cardiff Oncology earnings date?▼
Cardiff Oncology is going to release the next earnings report on April 30, 2026.
What were Cardiff Oncology earnings last quarter?▼
CRDF earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.19 USD resulting in a +41.8% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cardiff Oncology revenue for the last year?▼
Cardiff Oncology revenue for the last year amounts to 1.37M USD.
What is Cardiff Oncology net income for the last year?▼
CRDF net income for the last year is -90.91M USD.
How many employees does Cardiff Oncology have?▼
As of April 02, 2026, the company has 32 employees.
In which sector is Cardiff Oncology located?▼
Cardiff Oncology operates in the Health Care sector.
When did Cardiff Oncology complete a stock split?▼
The last stock split for Cardiff Oncology was on February 20, 2019 with a ratio of 1:6.
Where is Cardiff Oncology headquartered?▼
Cardiff Oncology is headquartered in San Diego, US.